Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Language
Year range
1.
Indian J Physiol Pharmacol ; 2010 Apr-June; 54(2): 99-122
Article in English | IMSEAR | ID: sea-145966

ABSTRACT

Stroke is one of the most important causes of mortality and morbidity in the world. Prevention and effective treatment of stroke is of the utmost importance. Cerebral ischemia causes disturbances in a variety of cellular and molecular mechanisms, including oxidative phosphorylation, membrane function, neurotransmitter release, and free radical generation. It has been years since tissue-type plasminogen activator (t-PA) became the first medication approved by the FDA for the management of stroke, with limited success. Thrombolytic therapy is the most effective therapeutic strategy for the prevention of brain injury and reduction of mortality in patients with cerebral infarction. However, a combination of established thrombolytic therapy and effective neuronal protection therapy may have more beneficial effects for patients with cerebral infarction. Because clinical trials of pharmacological neuroprotective strategies in stroke have been disappointing, attention has turned towards approaches which include herbal drugs that can be used in limiting the neurological damage associated with stroke. Herbal drugs may be used as prophylactic treatment in patients with high risk of stroke. Herbals drugs have been described in ancient systems of medicine for the treatment of various ailments associated with stroke and have more recently been reported to be beneficial in treating stroke. However, the strength of evidence to support the use of these herbal drugs is unclear. This review focuses on putative mechanisms underlying the beneficial effects of herbal drugs in patients with stroke and on the possibility of herbal drugs to increase the therapeutic time window in patients with cerebral ischemia.

2.
Indian J Physiol Pharmacol ; 2009 Jan-Mar; 53(1): 39-46
Article in English | IMSEAR | ID: sea-145903

ABSTRACT

The effect of curcumin, a dietary antioxidant was studied against kainic acid (KA)-induced seizures and on markers of oxidative stress. Rats were administered KA (10 mg/kg, ip) and observed for behavioral changes, incidence and latency of convulsions and mortality over four hours. The rats were thereafter sacrificed for estimation of oxidative stress parameters; malondialdehyde (MDA) and glutathione (GSH). Curcumin was administered 30 min before KA at doses of 50, 100 and 200 mg/kg, ip. KA induced long-lasting seizures and associated symptoms. The brain level of MDA was significantly (P<0.05) raised after KA administration (536±44 nmol/g wet tissue) as compared to saline treated group (200±36 nmol/g wet tissue) and significantly decreased the levels of GSH. Pretreatment with curcumin (100 and 200 mg/kg, ip) significantly increased the latency of seizures (120+20 min and 115±5.7 min respectively) as compared to the vehicle treated KA group. Curcumin (100 and 200 mg/ kg, ip) significantly prevented the increase in MDA levels and ameliorated the fall in glutathione. Curcumin at the dose of 50 mg/kg had no effect on any of oxidative stress parameters. The study reports the potential antiepileptic effect of antioxidant curcumin.

3.
Indian J Physiol Pharmacol ; 2006 Apr-Jun; 50(2): 157-62
Article in English | IMSEAR | ID: sea-107384

ABSTRACT

The present study was carried to investigate the effect of endothelin antagonist (TAK-044) in an in vitro model of stroke using primary neuronal culture. Hypoxia in neuronal culture was induced for 3 h using oxygen glucose deprivation (OGD) model, thereafter cells were reperfused. In separate group cultures were incubated with graded concentrations of TAK-044 (0.01, 0.1 and 1 microg/microl) for different time duration i.e. 6, 12 and 24 hours after reperfusion. Percent cell viability was assessed 24 h after reperfusion using MTT assay. It was observed that percent cell viability was reduced to 13.7 +/- 0.4% in the cells under 3 h hypoxic condition as compared to the cells under normal condition (100%). TAK-044 at the concentrations of 0.1 and 1 microg/microl, but not at 0.01 microg/microl showed significant (P<0.01) improvement in the % cell viability as compared to the cells in hypoxic condition. Percent cell viability at the concentration of 0.1 and 1 microg/microl for 24 h time duration after reperfusion were 54.8 +/- 3.2% and 75.4 +/- 1.8% respectively as compared to the cells under hypoxic condition (13.7 +/- 0.4%). The results demonstrate the neuroprotective effect of TAK-044 against neuronal damage caused by hypoxia induced in neuronal culture.


Subject(s)
Animals , Brain Ischemia/drug therapy , Cell Hypoxia , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Glucose/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Peptides, Cyclic/pharmacology , Rats , Stroke/drug therapy
4.
Indian J Physiol Pharmacol ; 2005 Oct-Dec; 49(4): 395-402
Article in English | IMSEAR | ID: sea-106481

ABSTRACT

In the present study, the effect of antioxidants-alpha lipoic acid, melatonin and trans resveratrol were studied against intracerebroventricular streptozotocin induced spatial memory deficit. Male Wistar rats were injected with intracerebroventricular streptozotocin bilaterally. The rats were treated chronically with alpha lipoic acid (200 mg/kg, po), melatonin (20 mg/kg, ip) and trans resveratrol (20 mg/kg, ip) for 18 days starting from day 1 of streptozotocin injection in separate groups. The spatial memory was evaluated using the Morris water maze task. The intracerebroventricular streptozotocin rats treated with antioxidants showed significantly less spatial memory deficit both in the acquisition and probe trials as compared to the vehicle treated rats. The study demonstrated the effectiveness of alpha lipoic acid, melatonin and trans resveratrol in preventing spatial memory deficit induced by intracerebroventricular streptozotocin and it's potential in age related neurodegenerative disorders where oxidative stress is involved such as Alzheimer's disease.


Subject(s)
Animals , Antioxidants/therapeutic use , Avoidance Learning/drug effects , Injections, Intraventricular , Male , Maze Learning/drug effects , Melatonin/therapeutic use , Memory Disorders/chemically induced , Rats , Rats, Wistar , Stilbenes/therapeutic use , Streptozocin/administration & dosage , Thioctic Acid/therapeutic use
5.
Indian J Physiol Pharmacol ; 2004 Oct; 48(4): 379-94
Article in English | IMSEAR | ID: sea-108102

ABSTRACT

Stroke is a major cause of death and disability worldwide. The resulting burden on the society continues to grow, with increase in the incidence of stroke. Brain attack is a term introduced to describe the acute presentation of stroke, which emphasizes the need for urgent action to remedy the situation. Though a large number of therapeutic agents like thrombolytics, NMDA receptor antagonists, calcium channel blockers and antioxidants, have been used or being evaluated, there remains a large gap between the benefits by these agents and properties an ideal drug for stroke should offer. In recent years much attention is being paid towards the exploration of herbal preparation, antioxidant agents and combination therapies including COX-2 inhibitors in experimental model of stroke. For better evaluation of the drugs and enhancement of their predictability from animal experimentation to clinical settings, it has been realized that the selection of animal models, the parameters to be evaluated should be critically assessed. Focal and global cerebral ischemia represents diseases that are common in the human population. Understanding the mechanisms of injury and neuroprotection in these diseases is important to learn new target sites to treat ischemia. There are many animal models available to investigate injury mechanisms and neuroprotective strategies. In this article we attempted to summarize commonly explored animal models of focal and global cerebral ischemia and evaluate their advantages and limitations.


Subject(s)
Animals , Brain Ischemia/drug therapy , Craniotomy , Disease Models, Animal , Humans , Stroke/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL